Intellia Therapeutics Inc (NTLA)
14.50
-0.16
(-1.06%)
USD |
NASDAQ |
Dec 04, 16:00
14.49
0.00 (0.00%)
After-Hours: 20:00
Intellia Therapeutics Enterprise Value: 833.97M for Dec. 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| December 03, 2024 | 833.97M |
| December 02, 2024 | 943.96M |
| November 29, 2024 | 932.76M |
| November 27, 2024 | 891.00M |
| November 26, 2024 | 842.12M |
| November 25, 2024 | 848.23M |
| November 22, 2024 | 798.32M |
| November 21, 2024 | 747.40M |
| November 20, 2024 | 678.14M |
| November 19, 2024 | 781.01M |
| November 18, 2024 | 785.08M |
| November 15, 2024 | 764.71M |
| November 14, 2024 | 881.84M |
| November 13, 2024 | 982.67M |
| November 12, 2024 | 1.038B |
| November 11, 2024 | 1.124B |
| November 08, 2024 | 1.046B |
| November 07, 2024 | 971.46M |
| November 06, 2024 | 977.57M |
| November 05, 2024 | 913.41M |
| November 04, 2024 | 883.87M |
| November 01, 2024 | 850.26M |
| October 31, 2024 | 789.43M |
| October 30, 2024 | 800.63M |
| October 29, 2024 | 867.81M |
| Date | Value |
|---|---|
| October 28, 2024 | 1.005B |
| October 25, 2024 | 965.54M |
| October 24, 2024 | 955.36M |
| October 23, 2024 | 1.372B |
| October 22, 2024 | 1.488B |
| October 21, 2024 | 1.446B |
| October 18, 2024 | 1.488B |
| October 17, 2024 | 1.478B |
| October 16, 2024 | 1.437B |
| October 15, 2024 | 1.329B |
| October 14, 2024 | 1.328B |
| October 11, 2024 | 1.233B |
| October 10, 2024 | 1.153B |
| October 09, 2024 | 1.139B |
| October 08, 2024 | 1.163B |
| October 07, 2024 | 1.158B |
| October 04, 2024 | 1.173B |
| October 03, 2024 | 1.139B |
| October 02, 2024 | 1.230B |
| October 01, 2024 | 1.296B |
| September 30, 2024 | 1.434B |
| September 27, 2024 | 1.442B |
| September 26, 2024 | 1.398B |
| September 25, 2024 | 1.411B |
| September 24, 2024 | 1.490B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
197.07M
Minimum
Mar 16 2020
12.46B
Maximum
Sep 03 2021
3.084B
Average
2.324B
Median
Enterprise Value Benchmarks
| BridgeBio Pharma Inc | 6.488B |
| Alnylam Pharmaceuticals Inc | 30.73B |
| Ionis Pharmaceuticals Inc | 4.449B |
| Pfizer Inc | 201.79B |
| Regeneron Pharmaceuticals Inc | 74.56B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -135.71M |
| Revenue (Quarterly) | 9.111M |
| Total Expenses (Quarterly) | 153.88M |
| EPS Diluted (Quarterly) | -1.34 |
| Profit Margin (Quarterly) | -1.49K% |
| Earnings Yield | -37.53% |
| Normalized Earnings Yield | -35.43 |